Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 5,913 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Cancer Clear all
Completed No phase listed Observational

Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases

NCT06675695
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
New use of osimertinib, New use of erlotinib or gefitinib
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

NCT04173507
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Avelumab, Talazoparib, Talazoparib Tosylate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
325
States / cities
Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00073866
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Not applicable Interventional

Real-time Activity Monitoring to Prevent Admissions During RadioTherapy

NCT03102229
View directory record Official record
Conditions
Cancer of the Head and Neck, Cancer of Lung, Cancer of Esophagus, Cancer of Stomach
Interventions
Enhanced Supportive Care - Status Checks, Enhanced Supportive Care - Referrals
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Completed No phase listed Observational

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202

NCT01503619
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

NCT02222922
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06647020 Q3W, fluconazole, PF-06647020 Q2W, PF-06647020 combined with Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

NCT02487095
View directory record Official record
Conditions
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
Interventions
Topotecan, VX-970 (M6620)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

NCT04374877
View directory record Official record
Conditions
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Interventions
CHS-388, Pembrolizumab, Toripalimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

NCT00570401
View directory record Official record
Conditions
Lung Cancer
Interventions
dasatinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 28, 2026, 4:31 PM EDT
Recruiting Phase 1 Interventional

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

NCT07192900
View directory record Official record
Conditions
Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions
locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
Biological · Drug
Lead sponsor
David Bartlett, MD
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

NCT04638751
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions
Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
Drug · Procedure
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Active, not recruiting Phase 1 Interventional

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03546361
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 28, 2026, 4:31 PM EDT
Terminated Not applicable Interventional

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

NCT01052766
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
PET/CT and BH PET/CT
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 28, 2026, 4:31 PM EDT
Active, not recruiting Not applicable Interventional

Testing the Engaged Approach to Lung Cancer Screening

NCT06327074
View directory record Official record
Conditions
Lung Cancer
Interventions
Engaged Approach to Lung Cancer Screening
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

NCT01263782
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Pemetrexed, Bevacizumab, Cixutumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 28, 2026, 4:31 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

NCT06383988
View directory record Official record
Conditions
Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Support for Caregiver - Generic List, Support for Caregiver - Personalized List, Internet-Based Intervention - CONNECT, Patient Navigation
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
25
States / cities
Denver, Colorado • Lafayette, Colorado • Lone Tree, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

NCT01266018
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ADI-PEG 20 (Arginine deiminase pegylated)
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 28, 2026, 4:31 PM EDT
Terminated Phase 1 Interventional Results available

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00288054
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, docetaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
77
States / cities
Anchorage, Alaska • Los Angeles, California • Marysville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

NCT00298896
View directory record Official record
Conditions
Carcinoma, Small Cell, Small Cell Lung Cancer
Interventions
SNS-595
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Sacramento, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

NCT00370383
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 28, 2026, 4:31 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Iadademstat + SBRT With Atezo in ES-SCLC

NCT07113691
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Iadademstat, Atezolizumab, SBRT
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 4:31 PM EDT
Completed Not applicable Interventional

Improving Implementation of Lung Cancer Screening in Diverse Populations II

NCT05265897
View directory record Official record
Conditions
Early Detection of Cancer, Lung Cancer
Interventions
CAQ
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 28, 2026, 4:31 PM EDT